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INTRODUCTION
TOLL-LIKE RECEPTORS: KEY RECEPTORS OF
THE INNATE IMMUNE SYSTEM
The human body constantly encounters a
diverse spectrum of pathogens. To defend
itself, a complex immune system has
evolved consisting of two subdivisions:
the innate and the adaptive immune sys-
tems. The innate immune system consti-
tutes the so-called “first line of defense”
and acts through highly conserved germ-
line-encoded pattern recognition receptors
(PRRs) (1). These receptors bind to com-
mon pathogen-associated molecular pat-
terns (PAMPs), which are vital for the sur-
vival of the microorganisms and cannot be
altered by mutations.
Pattern recognition receptors were first
discovered in the fruit fly Drosophila
melanogaster. The PRRs in Drosophila,
named Toll, play an important role in
the recognition of microorganisms such as
fungi as well as coordinating embryonic
development of the dorso-ventral axis.
Homologs of Toll in vertebrates are
called Toll-like receptors (TLRs). The first
TLR in humans was described in 1997
(2). To date, another 9 TLRs have been
identified in humans and 13 in mice.
Among these, only murine TLR10 is non-
functional due to retrovirus insertion (3).
Except for TLRs 3, 7, 8, and 9, which are
expressed intracellularly, TLRs are located
on the surface of innate and adaptive
immune cells as well as on non-immune
cells such as muscle cells, epithelial cells,
adipocytes, and pancreatic beta cells (1).
Cell-surface TLRs detect exogenous lipids,
lipoproteins, and proteins from microbes;
intracellular TLRs recognize bacterial and
viral nucleic acids (3). Recognition of their
cognate ligand triggers a complex sig-
naling cascade that ultimately results in
the induction of various pro-inflammatory
chemokines and cytokines and the activa-
tion of the adaptive immune system.
However, the activation of TLRs and
the subsequent induction of inflammatory
immune responses are not always benefi-
cial to the host. TLRs are involved in the
pathogenesis of various autoimmune and
non-infective inflammatory diseases such
as systemic lupus erythematosus, multi-
ple sclerosis, arteriosclerosis, inflammatory
bowel disease, diabetes, allergy, and cancer
(4, 5). Their activation can either attenuate
or boost the course of disease by induc-
ing tolerance or triggering autoreactivity,
respectively.
The role of the TLRs in the patho-
genesis of autoimmune-mediated diabetes,
also referred to as type 1 diabetes (T1D),
has been extensively studied (Table 1).
T1D is a T-cell-mediated metabolic disor-
der with progressive destruction of insulin-
producing pancreatic β cells (6). During
the course of disease development,diabeto-
genic T-cells, macrophages, and dendritic
cells will infiltrate the pancreatic islets and
cause islet inflammation and eventually β
cell loss.
This opinion letter focuses on the
beneficial and detrimental aspects of
TLR induction in the course of T1D
development.
TLR AND THEIR ROLE IN
AUTOIMMUNE-MEDIATED TYPE 1
DIABETES
TLR-MEDIATED INITIAL EVENTS IN THE
INDUCTION OF ISLET-DIRECTED IMMUNE
RESPONSES
One of the major functions of the immune
system is to distinguish self from non-self
in order to fight invaders (pathogens) while
sparing endogenous structures. PAMPs, the
ligands of TLRs, are conserved molecular
patterns that are exclusively expressed by
pathogens. Therefore, the innate immune
system is able to distinguish self and non-
self. This beneficial “discrimination” is fur-
ther enhanced by the adaptive immune
system, in which most of the self-reactive
T- and B-cells are deleted by central tol-
erance through negative selection. How-
ever, increasing evidence suggests that
TLRs also recognize endogenous molecules
including self-DNA released by injured or
dying cells. These endogenous molecules
act as danger signals and are therefore
called “danger-associated molecular pat-
terns (DAMPs).” The exposure of DAMPs
by necrotic cells is considered to be a
potential trigger of autoimmune diseases
such as T1D (24). Studies have shown
a defective clearance of dying cells in
the NOD mouse (25), currently the best
characterized model of human T1D (26).
Due to the diabetes-prone genetic back-
ground, this defect might essentially con-
tribute to the induction of autoimmunity
in these mice. The accumulation of apop-
totic β cells, which may undergo secondary
necrosis (so-called “late state apoptosis”),
could result in the activation of antigen-
presenting cells (APC) via TLR engage-
ment by released endogenous molecules
and thereby contributing to the induction
of diabetogenic T-cells (8, 27). Diabeto-
genic T-cells are then recruited to the pan-
creatic islets by chemokines like CCL2 (28,
29), CCL5, CXCL9, and CXCL10 (30) that
can be released from β cells upon TLR
ligation.
Consistent with this hypothesis is the
fact that TLR2 induces apoptosis (31)
and promotes diabetes in a streptozotocin-
induced diabetic model following activa-
tion via the synthetic ligand Pam3CSK4
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Table 1 |TLR-related studies in the field ofT1D.
TLR/adaptor protein TLR/adaptor protein Effect on the course ofT1D Reference
deficiency/
blockade
sufficiency attenuating/
protective
promoting/
boosting
dispensable
TLR2 + + Filippi et al. (7)
TLR2 + + + Kim et al. (8)
TLR2 + + Wen et al. (9)
TLR2 + + Devaraj et al. (10)
TLR2 + + Karumuthil-Melethil et al. (11)
TLR2 + + Al Shamsi et al. (12)
TLR2 + + Kim et al. (13)
TLR2, 3, 4, 7 + + Aumeunier et al. (14)
TLR3 + + Fallarino et al. (15)
TLR3 + + Wong et al. (16)
TLR4 + + Gülden et al. (17)
TLR4 + + Wen et al. (9)
TLR4 + + Devaraj et al. (18)
TLR4 + + Li et al. (19)
TLR7 + + Lee et al. (20)
TLR9 + + Zhang et al. (21)
TLR9 + + Tai et al. (22)
TLR9 + + Fallarino et al. (15)
TLR9 + + Zipris et al. (23)
TLR9 + + Wong et al. (16)
MyD88 + + Wen et al. (9)
The table displays only studies that addressed a TLR directly. The studies that used TLR ligands but did not directly demonstrate the role of a specific TLR are not
listed. ‘+’ denotes the composition (TLR or adaptor protein investigated; usage of wild type or knockout mice) and outcome of the study.
(12). The observation of delayed or
reduced diabetes onset in TLR9-deficient
mice further supports the theory (16, 21,
22). However, in a chemically induced dia-
betes mouse model, Fallarino et al. found
that TLR9-deficient C57BL/6 mice were
more susceptible to diabetes induction
(15). This opposing finding is most likely
due to the different choice of animal model.
Other investigators have used the NOD
mouse model (16, 21, 22) whereas Fallarino
and colleagues induced diabetes by injec-
tions of β cell-toxic drug streptozotocin to
C57BL/6 mice.
DISEASE PROTECTION VS. DISEASE
INDUCTION
As key receptors of the innate immune sys-
tem, TLRs trigger inflammatory immune
responses upon binding of cognate ligands.
On a predisposed genetic background, this
event might initiate islet inflammation fol-
lowed by progressive β cell destruction and
finally overt T1D.
However, TLR activation is not nec-
essarily causative for T1D development.
T1D-related studies summarized in
Table 1, reveal either a protective or
detrimental effect on the induction of
islet-directed autoimmunity. One reason
for this dichotomy might be the point in
time during the prediabetic phase when
TLR activation is induced. Moreover, the
presence or absence of β cell antigens
and/or endogenous DAMPs released by
late state apoptotic β cells possibly plays a
critical role. Studies showed that activation
of TLR2 (8), TLR3 (32), or TLR9 (33) by
their cognate ligands in the presence of β
cell antigens or DAMPs give rise to T1D
development, whereas TLR stimulation
in the absence of β cell antigens results in
tolerogenic immune responses (11, 34–36).
Observations by Filippi et al. suggest that
the reason for this outcome might be the
capacity of immunostimulatory factors to
augment immune regulation (7).
THE ROLE OF TLRs IN MODULATING Treg
FUNCTIONS
Regulatory T-cells (Treg) are TLR-
expressing adaptive immune cells which
control immune responses in order
to prevent aberrant immune reactions
which could be harmful (37). In the
presence of β cell antigens, TLR2 sig-
naling could, while inducing a pro-
inflammatory immune response, simul-
taneously promote suppressive Treg
functions.
Dasgupta et al. demonstrated that
engagement of TLR2 reverses the suppres-
sor function of conjunctiva Treg in rabbits
(38). In mice, in some cases, TLR2 stim-
ulation resulted in a temporary abroga-
tion of the regulatory capacity of Treg (39,
40), while other studies reported that the
Treg function was either unchanged (41)
or improved (7, 11). On the other hand,
studies by other investigators showed a
decreased number of Tregs following TLR2
stimulation (12).
One of the explanations for these con-
trary findings might be the different con-
centrations of the TLR ligand used in
their experimental systems. It has been
reported that the concentration of TLR
ligands influences the regulatory activity
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of Tregs (40, 42, 43). For example, Zanin-
Zhorov and colleagues showed that low
doses of the TLR2 ligand, Hsp60, resulted
in enhanced suppression without increased
Treg proliferation (42, 43).
Studies by Round and Mazman-
ian investigating the immunomodulatory
effect of polysaccharide A (PSA), a micro-
bial molecule of the commensal bacterium
Bacteroides fragilis, reveal that the PSA can
signal directly on Treg cells via their TLR2
and promote immune tolerance (44, 45). It
is possible that the effect may be accounted
for by the anatomical site where TLR2 is
engaged. Specifically in the intestine, TLR2
signaling induced by PSA is required for
Treg induction and IL-10 expression.
TLR2 ligation does not merely exert
influence on Treg; studies also reveal an
effect on effector T-cells (46, 47). TLR2 sig-
naling via Pam3Cys achieves resistance of
T effector cells toward Tregs (47).
Besides TLR2, other TLRs also modulate
Treg functions. TLR4 and TLR5 ligands are
capable of boosting the suppressive func-
tion of Treg on T effector cells (48, 49).
In line with these observations is the find-
ing that TLR4-deficient NOD mice exhibit
significantly accelerated diabetes develop-
ment and impaired suppressive function
of Tregs, although the frequency of Tregs
remains unchanged (17).
Taken together, TLRs act as important
modulators of Treg proliferation and func-
tion. Treg function can either be enhanced
or attenuated depending on the concentra-
tion of TLR ligands and the anatomical site
of TLR engagement.
TOLERANCE INDUCTION BY TLR SIGNALING
As potent activators of inflammatory
immune responses, the activation of TLRs
must be tightly controlled since over-
activation or loss of negative regulation can
lead to detrimental or even life-threatening
effects as seen in the condition of sepsis (50,
51). Repeated exposure to the same ligand
can therefore result in hyporesponsiveness
or tolerance through down-regulation of
TLRs and simultaneous up-regulation of a
negative feedback loop (50, 52).
In contrast to short term TLR stimula-
tion, which results in initiation of immune
responses, repeated exposure to TLR lig-
ands might lead to the abrogation of
inflammatory immune responses. In such
a manner, TLR2 tolerance and inhibi-
tion of T1D development in NOD mice
could be achieved by repeated adminis-
tration of the TLR2 agonist Pam3CSK4
or zymosan (11, 13). Decreased T1D inci-
dence was also accomplished following
treatment with LPS, poly (I:C) (34), or CpG
oligonucleotides (36).
As systemic chronic TLR stimulation
suppresses the development of T1D in
NOD mice (14, 53), it is possible that
the absence of TLR stimulation might
facilitate T1D development. This possibil-
ity is supported by the so-called hygiene
hypothesis (54). The hygiene hypothe-
sis coincides with the increase in allergy
and autoimmune diseases over the past
decades, possibly due to less exposure to
microbial products as the hygiene standard
has been significantly improved. Support-
ing the hygiene hypothesis is a recent study
revealing that NOD mice deficient in the
innate adaptor protein MyD88 are pro-
tected from diabetes development in non-
germ-free conditions but the protection
is abolished in germ-free conditions (9).
Furthermore, introducing gut commensals
into germ-free mice re-establishes the pro-
tection. This study supports the crucial role
of environmental (TLR) stimuli in modu-
lating the pathogenesis of diabetes through
commensal bacteria.
CONCLUDING REMARKS
The important role of TLRs in the patho-
genesis of T1D manifests mainly in their
ability to induce APC maturation and
to produce inflammatory chemokines and
cytokines. These two features will con-
tribute to the priming of autoreactive T-
cells, which cause islet cell destruction.
However, TLR signaling can also induce
immune tolerance that results in diabetes
prevention depending on the genetic back-
ground and the environment.
Increasing evidence suggests that TLRs
also express on tissue cells including pan-
creatic beta cells. The role of TLRs on islet
beta cells is largely unknown. Due to the
complexity of the T1D pathogenesis, there
is still no cure or ultimate prevention from
the disease development. TLRs are criti-
cal modulators of islet-directed immune
responses and are, therefore, important tar-
gets for anti-diabetogenic therapies. How-
ever, many functions of TLRs and causal
relations are still unknown. Many ques-
tions must be answered before we can
generate novel and effective therapeutic
approaches that target TLRs in treating
T1D. Since therapeutic targeting of TLRs
can also increase the susceptibility toward
infections, safety and efficacy have to
be thoroughly balanced when modulating
TLRs.
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